Literature DB >> 9935161

EGF-related peptides are involved in the proliferation and survival of MDA-MB-468 human breast carcinoma cells.

A De Luca1, A Casamassimi, M P Selvam, S Losito, F Ciardiello, S Agrawal, D S Salomon, N Normanno.   

Abstract

A majority of human breast carcinomas co-express the epidermal growth factor (EGF)-like peptides CRIPTO (CR), amphiregulin (AR) and transforming growth factor alpha (TGF-alpha). MDA-MB-468 breast carcinoma cells express CR, AR and TGFalpha, while SK-BR-3 cells express CR and TGF-alpha. Anti-sense phosphorothioate oligodeoxynucleotides (AS S-oligos) directed against either CR or TGF-alpha inhibit the proliferation of both cell lines. A 40-50% growth inhibition was observed at a 2-microM concentration of each AS S-oligo. Treatment with the AR AS S-oligo also resulted in a significant inhibition of MDA-MB-468 anchorage dependent growth (ADG). No significant growth inhibition was observed when MDA-MB-468 or SK-BR-3 cells were treated with a mis-sense S-oligo. The AS S-oligos inhibited the expression of AR, CR or TGF-alpha proteins and mRNAs, as assessed by immuno-cytochemistry and semi-quantitative RT-PCR. An additive growth-inhibitory effect was observed when MDA-MB-468 cells were treated with a combination of EGF-related AS S-oligos. Indeed, treatment of MDA-MB-468 cells with a combination of AR, CR and TGF-alpha AS S-oligos resulted in about 70% growth inhibition at a concentration of 0.7 microM each. Finally, treatment of MDA-MB-468 cells with a combination either of the 3 AS S-oligos or of an EGF receptor-blocking antibody (MAb 225) and either CR, AR or TGFalpha AS S-oligos resulted in a significant increase in DNA fragmentation. Our data suggest that the EGF-related peptides are involved in the proliferation and survival of breast carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9935161     DOI: 10.1002/(sici)1097-0215(19990209)80:4<589::aid-ijc17>3.0.co;2-d

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Targeting the embryonic gene Cripto-1 in cancer and beyond.

Authors:  Caterina Bianco; David S Salomon
Journal:  Expert Opin Ther Pat       Date:  2010-11-13       Impact factor: 6.674

Review 2.  The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition.

Authors:  Malgorzata Klauzinska; Nadia P Castro; Maria Cristina Rangel; Benjamin T Spike; Peter C Gray; Daniel Bertolette; Frank Cuttitta; David Salomon
Journal:  Semin Cancer Biol       Date:  2014-08-19       Impact factor: 15.707

3.  The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.

Authors:  Qing-Bai She; David B Solit; Qing Ye; Kathryn E O'Reilly; Jose Lobo; Neal Rosen
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

4.  Expression and functional role of CRIPTO-1 in cutaneous melanoma.

Authors:  A De Luca; L Lamura; L Strizzi; C Roma; A D'Antonio; N Margaryan; G Pirozzi; M-Y Hsu; G Botti; E Mari; M J C Hendrix; D S Salomon; N Normanno
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

5.  CRIPTO antagonist ALK4L75A-Fc inhibits breast cancer cell plasticity and adaptation to stress.

Authors:  Ozlen Balcioglu; Richard E Heinz; David W Freeman; Brooke L Gates; Berhane M Hagos; Evan Booker; Elnaz Mirzaei Mehrabad; Hyrum T Diesen; Kishan Bhakta; Supraja Ranganathan; Masami Kachi; Mathias Leblanc; Peter C Gray; Benjamin T Spike
Journal:  Breast Cancer Res       Date:  2020-11-13       Impact factor: 6.466

6.  The EGFR Signaling Modulates in Mesenchymal Stem Cells the Expression of miRNAs Involved in the Interaction with Breast Cancer Cells.

Authors:  Marianna Gallo; Marianeve Carotenuto; Daniela Frezzetti; Rosa Camerlingo; Cristin Roma; Francesca Bergantino; Nicola Normanno; Antonella De Luca
Journal:  Cancers (Basel)       Date:  2022-04-06       Impact factor: 6.639

7.  Cripto haploinsufficiency affects in vivo colon tumor development.

Authors:  Emilia Giorgio; Annamaria Liguoro; Luca D'Orsi; Sara Mancinelli; Antonio Barbieri; Giuseppe Palma; Claudio Arra; Giovanna L Liguori
Journal:  Int J Oncol       Date:  2014-04-30       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.